EUVIMEDEUVIMED entdecken
Open Access

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

Mackenzie J Bender, Alex C McPherson, Catherine M Phelps, Surya P Pandey, Colin R Laughlin, Jake H Shapira, Luzmariel Medina Sanchez, Mohit Rana, Tanner G Richie, Tahliyah S Mims, Angela M Gocher-Demske, Luisa Cervantes-Barragan und 13 weitere

Cell · 2023-04 · 186 (9) · 1846-1862.e26

DOI: 10.1016/j.cell.2023.03.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2023-04. Verfasst von Mackenzie J Bender und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Limosilactobacillus reuteri, Melanoma, Tumor Microenvironment. Die Arbeit wurde bisher 738-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of probiotics by cancer patients is increasing, including among those undergoing immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host crosstalk between probiotic-released aryl hydrocarbon receptor (AhR) agonist indole-3-aldehyde (I3A) and CD8 T cells within the tumor microenvironment that potently enhances antitumor immunity and facilitates ICI in preclinical melanoma. Our study reveals that probiotic Lactobacillus reuteri (Lr) translocates to, colonizes, and persists within melanoma, where via its released dietary tryptophan catabolite I3A, it locally promotes interferon-γ-producing CD8 T cells, thereby bolstering ICI. Moreover, Lr-secreted I3A was both necessary and sufficient to drive antitumor immunity, and loss of AhR signaling within CD8 T cells abrogated Lr's antitumor effects. Further, a tryptophan-enriched diet potentiated both Lr- and ICI-induced antitumor immunity, dependent on CD8 T cell AhR signaling. Finally, we provide evidence for a potential role of I3A in promoting ICI efficacy and survival in advanced melanoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Limosilactobacillus reuteriMelanomaTumor MicroenvironmentHumansDietImmune Checkpoint InhibitorsTryptophanCD8-Positive T-LymphocytesReceptors, Aryl Hydrocarbon

Stichwörter der Autor:innen

Lactobacillus reuteriaryl hydrocarbon receptorimmune checkpoint inhibitorindole-3-aldehydemelanomamicrobial AhR ligandsmicrobial-host crosstalktryptophantumor microbiome

Substanzen

Immune Checkpoint InhibitorsTryptophanReceptors, Aryl Hydrocarbon

Autor:innen und Institutionen

  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Infectious Diseases and Microbiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA.
  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Graduate Program of Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Division of Biology, Kansas State University, Manhattan, KS, USA.
  • Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, WI, USA.
  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health
  • School of Dental Medicine, University of Pittsburgh
  • Melanoma Research Alliance

Zitieren

APA

Bender, M. J., McPherson, A. C., Phelps, C. M., Pandey, S. P., Laughlin, C. R., Shapira, J. H., Medina Sanchez, L., Rana, M., Richie, T. G., Mims, T. S., Gocher-Demske, A. M., Cervantes-Barragan, L., Mullett, S. J., Gelhaus, S. L., Bruno, T. C., Cannon, N., McCulloch, J. A., Vignali, D. A. A., Hinterleitner, R., …, & Meisel, M. (2023). Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell, 186(9), 1846-1862.e26. https://doi.org/10.1016/j.cell.2023.03.011

Vancouver

Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023;186(9):1846-1862.e26. doi:10.1016/j.cell.2023.03.011

BibTeX
@article{Bender2023,
  author = {Bender, Mackenzie J and McPherson, Alex C and Phelps, Catherine M and Pandey, Surya P and Laughlin, Colin R and Shapira, Jake H and Medina Sanchez, Luzmariel and Rana, Mohit and Richie, Tanner G and Mims, Tahliyah S and Gocher-Demske, Angela M and Cervantes-Barragan, Luisa and Mullett, Steven J and Gelhaus, Stacy L and Bruno, Tullia C and Cannon, Nikki and McCulloch, John A and Vignali, Dario A A and Hinterleitner, Reinhard and Joglekar, Alok V and Pierre, Joseph F and Lee, Sonny T M and Davar, Diwakar and Zarour, Hassane M and Meisel, Marlies},
  title = {Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment},
  journal = {Cell},
  year = {2023},
  volume = {186},
  number = {9},
  pages = {1846--1862.e26},
  doi = {10.1016/j.cell.2023.03.011}
}
Kostenlos starten →